Tumor and immune reprogramming during immunotherapy in ...

Immune checkpoint blockade (ICB) results in durable disease control in a subset of patients with advanced renal cell carcinoma (RCC), ...

Article Tumor and immune reprogramming during immunotherapy in ...

Our findings demonstrate that ICB remodels the RCC microenvironment and modifies the interplay between cancer and immune cell populations.

Cancer Cell, Volume 39. Supplemental information. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Kevin Bi, Meng Xiao He ...

Tumor and immune reprogramming during immunotherapy in ...

Immune checkpoint blockade (ICB) results in durable disease control in a subset of patients with advanced renal cell carcinoma (RCC), but mechanisms driving ...

Tumor and immune reprogramming during immunotherapy in ...

In cancer cells, we identify bifurcation into two subpopulations differing in angiogenic signaling and upregulation of immunosuppressive ...

(PDF) Tumor and immune reprogramming during immunotherapy in ...

The tumor immune microenvironment plays a critical role in cancer progression and response to immunotherapy in clear cell renal cell carcinoma (ccRCC), yet the ...

Reprogramming Immune Cells for Enhanced Cancer Immunotherapy

Immunotherapy is becoming a revolutionary clinical management for various cancer types. Restoration of aberrant immune surveillance on cancers has achieved ...

Reprogramming the tumor immune microenvironment using ... - Nature

In light of this limitation, targeted anti-tumor approaches with advantages over conventional approaches might represent the next generation of ...

Divergent tumor and immune cell reprogramming underlying ...

However, ICIs could also lead to a unique spectrum of immune-related adverse events (irAEs), which dampen the clinical outcome. In-depth characterization of the ...

In vivo dendritic cell reprogramming for cancer immunotherapy

These include dendritic cells (DCs) that capture and present tumor antigens to T cells. Therefore, it has been challenging to achieve ...

Cell Fate Reprogramming in the Era of Cancer Immunotherapy

Dendritic cell-based vaccines are being explored to reactivate anti-tumor adaptive immunity. Immune checkpoint inhibitors and chimeric antigen receptor T-cells ...

Dana-Farber research leads to better understanding of the immune ...

With immunotherapy, patients are typically given an immune checkpoint blockade (ICB) (often in combination with VEGF tyrosine kinase inhibitors; ...

Reprogramming the immunosuppressive tumor microenvironment ...

Meanwhile, a wide range of tumor cell-derived toxic metabolites exerts negative impacts on anti-tumor immune response, diminishing the efficacy of immunotherapy ...

Reprogramming-based gene therapy promotes anti-tumor immunity ...

Cancer immunotherapy induces a tumor antigen-specific T lymphocyte response that kills tumor cells. Dendritic cells, specifically ...

Reprogramming the Tumor Microenvironment to Improve ...

In cases where the immune response to cancer results in increased TH1 cytokines by adaptive cells (e.g., CD4+ T cells and natural killer [NK] ...

Reprogramming Turns Cancer Cells into Immune Allies

The reprogramming-meets-immunotherapy modality detailed in the latest report comes from Filipe Pereira, PhD, and his colleagues at Lund ...

A better understanding of the immune system in kidney cancer

The other study published today looks at tumor and immune reprogramming during immunotherapy in ccRCC. Most current immunotherapy treatments for ...

Reprogramming the immunosuppressive tumor microenvironment

A key pathway through which tumors evade the immune system is the reprogramming ... immune microenvironment to facilitate tumor immune evasion and immunotherapy ...

Infiltrating treg reprogramming in the tumor immune ...

Immunotherapy has shown promising anti-tumor effects across various tumors, yet it encounters challenges from the inhibitory tumor immune ...

Reprogramming tumor cells to fight cancer - Science

This strategy may also be beneficial when used in combination with other immunotherapies for the treatment of immune-desert tumors (those ...